Top

Published in:

01-06-2011

Use of Testosterone Replacement Therapy in Patients with Prostate Cancer

Authors: Tanya B. Dorff, Nicholas J. Vogelzang

Published in: Current Urology Reports | Issue 3/2011

Abstract

Prostate cancer is among the more common and less lethal malignancies, yielding a large population of survivors. The incidence of hypogonadism increases in the same elderly population of men who most frequently develop prostate cancer, and the risk of becoming hypogonadal is increased further by prostate cancer therapy. The relative safety of replacing testosterone to reduce symptoms of hypogonadism in men who have been treated for prostate cancer is not well established. We review the available data, provide suggestions for approaching the management of prostate cancer survivors who suffer hypogonadal symptoms, and describe other diagnostic and therapeutic uses of testosterone that have been employed in patients with prostate cancer.

Kamanagar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRef

Harman SM, Metter E, Tobin EJ, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. J Clin Endocrinol Metab. 2001;86:724.PubMedCrossRef

Nejat RJ, Rashid HH, Bagiella E, et al. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol. 2000;164:1891–4.PubMedCrossRef

Pickles T, Agranovich A, Berthelet E, et al. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma. Cancer. 2002;94:362–7.PubMedCrossRef

Smith MR, Finkelstein JS, McGovern FJ, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab. 2002;87:599–603.PubMedCrossRef

Keating NL, O’Malley J, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–53.PubMedCrossRef

Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2004;89:5462–8.PubMedCrossRef

Saigal CS, Gore JL, Krupski TL, et al. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493–500.PubMedCrossRef

Bhasin S, Storer TW, Berman N, et al. Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. J Clin Endocrinol Metab. 1997;82:407–13.PubMedCrossRef

10.

Wang C, Swerdloff RS, Iranmanesh A, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85:2839–53.PubMedCrossRef

11.

Kapoor D, Goodwin E, Channer KS, Jones TH. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899–906.PubMedCrossRef

12.

Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol. 2008;179:152–5.PubMedCrossRef

13.

Smith MR, Malkowicz SB, Chu F, et al. Toremifene improves lipid profiles in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study. J Clin Oncol. 2008;26:1824–9.PubMedCrossRef

14.

Huggins CB, Stevens RB, Hodges CV. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg. 1941;43:209.

15.

Soto AM, Sonnenschein C. The two faces of Janus: sex steroids as mediators of both cell proliferation and cell death. J Natl Cancer Inst. 2001;93:1673.PubMedCrossRef

16.

Wang YZ, Wong YC. Sex hormone-induced prostatic carcinogenesis in the noble rat: the role of insulin-like growth factor-I (IGF-1) and vascular endothelial growth factor (VEGF) in the development of prostate cancer. Prostate. 1998;35:165–77.PubMedCrossRef

17.

Curran MJ, Bihrle W. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology. 1999;53:423–4.PubMedCrossRef

18.

Loughlin KR, Richie JP. Prostate cancer after exogenous testosterone treatment for impotence. J Urol. 1997;157:1845.PubMedCrossRef

19.

Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. New Engl J Med. 2004;350:482–92.PubMedCrossRef

20.

Rhoden EL, Morgentaler A. Testosterone replacement therapy in hypogonadal men at high risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol. 2003;170:2348–51.PubMedCrossRef

21.

Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism. JAMA. 2006;296:2351–61.PubMedCrossRef

22.

Sohlberg O, Brawer MK, Matsumoto A, Lange PH. Androgen provocative Testing (APT) after radical prostatectomy. J Urol 1990; 143: abstr 507.

23.

• Sarosdy MF. Testosterone replacement for hypogonadism after treatment of early prostate cancer with brachytherapy. Cancer. 2007;109:536–41. This series reports on outcomes for a homogeneous population of men treated with TRT after brachytherapy. PubMedCrossRef

24.

Morales A, Black AM, Emerson LE. Testosterone administration to men with testosterone deficiency syndrome after external beam radiotherapy for localized prostate cancer: preliminary observations. BJU Int. 2009;103:62–4.PubMedCrossRef

25.

Gerstenbluth RE, Maniam PN, Corty EW, Seftel AD. Prostate-specific antigen changes in hypogonadal men treated with testosterone replacement. J Androl. 2002;23:922–6.PubMed

26.

Agarwal PK, Oefelein MG. Testosterone replacement therapy after primary treatment for prostate cancer. J Urol. 2005;173:533–6.PubMedCrossRef

27.

Kaufman JM, Graydon RJ. Androgen replacement after curative radical prostatectomy for prostate cancer in hypogonadal men. J Urol. 2004;172:920–2.PubMedCrossRef

28.

Khera M, Grober ED, Najari B, et al. Testosterone replacement therapy following radical prostatectomy. J Sex Med. 2009;6:1165–70.PubMedCrossRef

29.

• Leibowitz R, Dorff TB, Tucker S, et al. Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU Int. 2010;105:1397–401. This series is heterogeneous, but provides some description of outcomes for men treated with TRT who have prostate in place and/or metastatic disease. PubMedCrossRef

30.

Bruchovsky N, Goldenberg SL, Gleave M. Interittent hormonal therapy for prostate cancer in Adv Urology 1997, vol 10 in Mosby-Year Book.

31.

Sato N, Gleave ME, Bruchovsky N, et al. Intermittent androgen deprivation delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumor model. J Steroid Biochem Mol Biol. 1996;58:139–46.PubMedCrossRef

32.

Fowler JE, Whtimore WF. The response of metastatic adenocarcinoma of the prostate to exogenous testosterone. J Urol. 1981;126:372–5.PubMed

33.

• Morris MJ, Huang D, Kelly WK, et al. Phase I trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate. Eur Urol. 2009;56:237–44. This clinical trial escalated duration rather than dose of TRT and documented safety. PubMedCrossRef

34.

• Szmulewitz R, Mohile S, Posadas E, et al. A randomized phase I study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol. 2009;56:97–104. This trial escalated doses of TRT and documented safety, with some PSA declines. PubMedCrossRef

35.

Rathkopf D, Carducci MA, Morris MJ, et al. Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer. J Clin Oncol. 2008;26:2959–65.PubMedCrossRef

36.

Stephenson AJ, Scardino PT, Eastham JA, et al. Post-operative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2005;23:7005–12.PubMedCrossRef

37.

Geck P, Maffini MP, Szelei J, et al. Androgen-induced proliferative quiescence in prostate cancer: the role of AS3 as its mediator. Proc Natl Acad Sci. 2000;97:10185–90.PubMedCrossRef

38.

Kahn SM, Li YH, Hryb DJ, et al. Sex hormone-binding globulin influences gene expression of LNCaP and MCF-7 cells in response to androgen and estrogen treatment. Adv Exp Med Biol. 2008;617:557–64.PubMedCrossRef

39.

Sonnenschein C, Olea N, Pasanen ME, Soto AM. Negative controls of cell proliferation: human prostate cancer cells and androgens. Cancer Res. 1989;49:3474–81.PubMed

40.

Attard G, Reid AHM, A’Hern R, et al. Selective inhibition of cyp17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009;27:3742–8.PubMedCrossRef

Title: Use of Testosterone Replacement Therapy in Patients with Prostate Cancer
Authors: Tanya B. Dorff
Nicholas J. Vogelzang
Publication date: 01-06-2011
Publisher: Current Science Inc.
Published in: Current Urology Reports / Issue 3/2011
Print ISSN: 1527-2737
Electronic ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-011-0176-2

At a glance: The STEP trials

Springer Medicine

Use of Testosterone Replacement Therapy in Patients with Prostate Cancer

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2011

Androgen Suppression Strategies for Prostate Cancer: Is There an Ideal Approach?

Robotic High-intensity Focused Ultrasound for Prostate Cancer: What Have We Learned in 15 Years of Clinical Use?

Complications of Pelvic Lymph Node Dissection for Prostate Cancer

Current Clinical Trials in Castrate-Resistant Prostate Cancer

Update on Prostate Brachytherapy: Long-term Outcomes and Treatment-related Morbidity

Salvage Cryotherapy for Radiation-Recurrent Prostate Cancer: Outcomes and Complications